Brilliant visualization

See the difference to make big breakthroughs in your tumor microenvironment research

In the world of next generation immuno-oncology research, having confidence in your immunoassay results is vital. Unfortunately, 75% of antibodies in today’s market are non-specific or simply do not work at all.* That’s why at Bethyl, we manufacture and validate every antibody on-site to ensure target specificity and sensitivity. More than 10,000 independent citations over the past 15 years have proven that our antibodies will function as designed in your assay — and we offer a 100% guarantee.

Work with Bethyl to bring your discovery into full focus.

Brilliant visualization

See the difference to make big breakthroughs in your tumor microenvironment research

In the world of next generation immuno-oncology research, having confidence in your immunoassay results is vital. Unfortunately, 75% of antibodies in today’s market are non-specific or simply do not work at all.* That’s why at Bethyl, we manufacture and validate every antibody on-site to ensure target specificity and sensitivity. More than 10,000 independent citations over the past 15 years have proven that our antibodies will function as designed in your assay — and we offer a 100% guarantee.

Work with Bethyl to bring your discovery into full focus.

Immuno-oncology has moved from an emerging field to one of the cornerstones of cancer therapy. Unlike traditional therapies such as radiation or chemotherapy which target the tumor itself, immunotherapy stimulates the patient’s own immune system to target and eradicate cancerous cells. In order to attack cancerous cells, the immune system must be able to respond in several ways. First, antigen presenting cells (APC) such as macrophages and dendritic cells must process tumor associated antigens (TAA) derived from dying cancer cells and display them on their surface via MHC-II receptors. Second, antigen presenting cells must generate a protective T-cell population. Last, cancer-specific, CD8+ cytotoxic T-cells must evade immunosuppressive (checkpoints) signals being expressed in the tumor.

Successful inhibition of the PD-1 and CTLA-4 signaling systems have revolutionized treatment options.

Early immunotherapy ideas involved using vaccines to present tumor associated antigens to APCs. Recently, the most exciting therapies have involved clearing the immunosuppressive signals within the tumor using checkpoint inhibitors. Successful inhibition of the PD-1 and CTLA-4 signaling systems have revolutionized treatment options. The identification of other receptor systems such as Tim-3, Lag-3, and OX40, which down regulate T-cells, has expanded the possibility of new checkpoint inhibitors.

As different immunotherapies have become available as treatment options, it is clear that not every patient responds. Thus, profiling the tumor microenvironment to determine the type of immune cells present and expression of immunosuppressive signals within the tumor is a key component of designing new therapies and predicting responsive patients.

Bethyl maintains an extensive catalog of antibodies that can be used to identify immune cell type, tumor cells, and the presence of checkpoint inhibitors.

Interested in Multiplexing?

Accelerate your cancer discoveries with our multiplex antibody panels optimized for immuno-oncology applications.

Detection of human CD8 (red) and FoxP3 (green) in FFPE colon carcinoma. Rabbit anti-CD8a recombinant monoclonal [BLR044F] (A700-044) and rabbit anti-FoxP3 recombinant monoclonal [BLR034F] (A700-034). Secondary: HRP-conjugated goat-anti-rabbit IgG (A120-501P) Substrate: Opal™ 590 and 520. Counterstain: DAPI (blue).

Detection of human CD3 (green), CD20 (magenta), CD68 (yellow), and Cytokeratin (red) in FFPE human NSCLC. Antibodies: Rabbit anti-CD3E recombinant monoclonal [BL-298-5D12] (A700-016), mouse anti-CD20 monoclonal [L26] (A500-017A), mouse anti-CD68 recombinant monoclonal [KP-1] (A500-018A), mouse anti-Cytokeratin monoclonal [AE1/AE3] (A500-019A). Substrate: Opal™ reagent. Counterstain: DAPI (blue).

 

Detection of human VISTA (orange) in FFPE human tonsil. Antibody: Rabbit anti-VISTA recombinant monoclonal [BLR035F] (A700-035). Secondary: HRP-conjugated goat-anti-rabbit IgG (A120-501P). Substrate: Opal™ 620. Counterstain: DAPI (blue).

Competitor Comparisons

Each assay was performed in accordance to the manufacturer’s recommended protocol as outlined in each product’s datasheet.

Competitor Comparison #1

Competitor’s Rabbit anti-PD-L1 Monoclonal Antibody
 

Application: IHC
Sample: Lung carcinoma

Bethyl’s Rabbit anti-PD-L1 Recombinant Monoclonal Antibody
[BLR020E] A700-020-1

Application: IHC
Sample: Lung carcinoma

Competitor Comparison #2

Competitor A’s Rabbit anti-PD-L1 Monoclonal Antibody
 

Application: IHC
Sample: Tonsil

Competitor B’s Rabbit anti-PD-L1 Monoclonal Antibody
 

Application: IHC
Sample: Tonsil

Bethyl’s Rabbit anti-PD-L1 Recombinant Monoclonal Antibody
[BLR020E] A700-020-1

Application: IHC
Sample: Tonsil

Competitor Comparison #3

Competitor’s Rabbit anti-CD3E Monoclonal Antibody
 

Application: IHC
Sample: Tonsil

Bethyl’s Rabbit anti-CD3E Recombinant Monoclonal Antibody
[BL-298-5D12] A700-016-1

Application: IHC
Sample: Tonsil

Get our Multiplex IHC Poster

Multiplex immunohistochemistry (mIHC) enables the tracking of multiple markers within the tumor microenvironment. See the advantages of Multiplex IHC.

Get this Tumor Immune Microenvironment Supplement

The reviews and research in this supplement offer a snapshot of the latest advances in research into the roles and regulation of immune cells in cancer.

Get our Stars of the Show Poster

Get the full picture with trusted tumor immune response results from our in-house validated antibodies.

Get this Immune Checkpoints in Cancer Therapy Supplement

This collection showcases the current progress from genomic and proteomic approaches that are providing a view into the responses to checkpoint blockade therapies to mechanistic studies that are defining the biochemical pathways that mediate an active response or resistance.

Antibodies for Immuno-Oncology Research

Immune Cells and Tumor Microenvironment

The tumor microenvironment contains normal cells, tumor cells, lymphocytes, and blood vessels. The identification and interaction of these tumor microenvironment constituents aids in diagnostics, treatment and response measures.

Immune Cell Type Markers

Pan-immune Cells
CD45
A700-012 & A300-376A

CD3/CD3E
A304-291

T-cell
CD3/CD3E
A700-016

CD247/CD3Z
A700-017

B-cell
CD20
A500-017A

General APC Cells
CD54/ICAM-1
A302-873A & A302-874A

 

Macrophage
CD68
A500-018A

CD86
A700-029
A700-030

HLA-DR
A500-022A

IDO1
A700-031

Natural Killer Cells
CD7
A304-396A

CD117/c-Kit
A303-252A

Tumor Cell Markers

Proliferation
Ki-67
A700-021, IHC-00375 & IHC-00395

PCNA
A300-276A, A300-276B, A300-277A, A300-277B & IHC-00012

Epithelial
Cytokeratin
A500-019A

Mesenchymal
Vimentin
A301-620A & IHC-00314

Angiogenesis
CD31
IHC-00055

T-Cell Markers

The ability of the immune system to respond to cancer is dependent on T-cells specific for tumor-associated antigens. Both immune related cells and tumor cells can influence the activation state of T-cells. The ability to phenotype activation status and sub-categories of T-cells present in the tumor microenvironment is important for predicting immune response towards the tumor.

T-cell Markers
CD3/CD3E
A700-016 & A304-291

CD247/CD3Z
A700-017

Helper T-cell
CD4
A700-015

Cytoxic T-cell
CD8
A500-021A

Granzyme B
A700-022

Memory T-cell
CD45RO
A500-020A

Immune Checkpoints

Tumors suppress immune responses by the activation of negative signaling pathways termed immune checkpoints or co-inhibitory pathways. The ability of T-cells to mount an effective response is also dependent the presence of co-stimulatory signaling. The characterization of the repertoire of inhibitory and stimulatory molecules can help determine the type of immunotherapy which will generate the most effective patient response.

Co-inhibitory
PD-L1
A700-020

B7-H3/CD276
A700-025

B7-H3/CD276
A700-026

LAG3
A700-027

 
LAG3
A700-028

TIM3
A700-033

B7-H4
A700-043

VISTA
A700-035

Co-stimulatory

OX40/CD134
A700-042

CD137
A700-051

CD40
A700-056

Looking for a specific target that's not listed?

Guarantee Statement

Bethyl is dedicated to delivering the highest standards of product and service quality. Recognizing that your research and time are valuable, we promise to stand behind our products. Should one of our antibodies fail to return satisfactory results when used in the species, application and under the same conditions stated on the product datasheet, Bethyl will offer a full product replacement, credit or refund at the investigator’s discretion. Before providing product replacement, credit or refund, we ask the investigator to complete an application specific questionnaire and work with our Technical Support team to identify potential steps to optimize conditions.

Every Bethyl product ships with a 100% guarantee; choose Bethyl antibodies with confidence.

Bethyl Laboratories, Inc. • P.O. Box 850 • Montgomery, TX 77356
1-800-338-9579 • Fax: 1-866-597-6105
© 2019 - Bethyl Laboratories, Inc. All rights reserved.